Intermittent Treatment with Farnesyltransferase Inhibitor and Sulforaphane Improves Cellular Homeostasis in Hutchinson-Gilford Progeria Fibroblasts

The study investigated the effects of intermittent treatment with a farnesyltransferase inhibitor (FTI) and sulforaphane (SFN) on cellular homeostasis in fibroblasts from patients with Hutchinson-Gilford progeria syndrome (HGPS). The researchers found that a 4-day regimen (1 day of FTI followed by 3 days of SFN) improved several cellular functions, including nuclear morphology, DNA damage response, and oxidative stress levels, more effectively than single-drug treatments or continuous combined treatment, which was cytotoxic. These findings suggested that the intermittent administration of FTI and SFN could be a promising therapeutic strategy for managing cellular defects in HGPS.